Improved Protection Against Solar-Simulated Radiation-Induced Immunosuppression by a Sunscreen with Enhanced Ultraviolet A Protection  Amy Fourtanier, Audrey Gueniche, Delphine Compan  Journal of Investigative Dermatology  Volume 114, Issue 4, Pages 620-627 (April 2000) DOI: 10.1046/j.1523-1747.2000.00946.x Copyright © 2000 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 The emission spectra of the xenon sources comply with recognized standards. The SSR spectrum (- - -) meets the COLIPA standard for SPF testing. Spectra for human and mouse studies were superimposable. The UVA spectrum (–-) meets the JCIA standard for UVA-PF determinations in humans. The spectra were measured with an increment step of 1 mm and are shown in relative units (the spectra were divided by the SSR total irradiance). Journal of Investigative Dermatology 2000 114, 620-627DOI: (10.1046/j.1523-1747.2000.00946.x) Copyright © 2000 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Two broad-spectrum sunscreens with similar SPF show differences in UVA absorption. The mPF spectra of products 5-A (- - -) and 5-B (–-) were generated by spectroradiometric measurements between 290 and 400 nm according to a modified Diffey method (Diffey & Robson 1989). The sunscreens were applied to roughened quartz plates at 1 mg per cm2. These spectra clearly show that the efficacy of product 5-A is much higher than 5-B in the UVA range. Journal of Investigative Dermatology 2000 114, 620-627DOI: (10.1046/j.1523-1747.2000.00946.x) Copyright © 2000 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 3 Two broad-spectrum sunscreens (SPF 7–8) afford comparable protection from erythema and edema over the SSR dose range tested (4–16 MED). There was a significant (p < 0.05) SSR dose-dependent increase in the two inflammation endpoints. (a) The dose–response curves for erythema in the different experimental groups are superimposed when EryPF is 6.9 for sunscreen 5-A and 7.2 for sunscreen 5-B. (b) For edema curves superimpose when EdPF is 5 for sunscreen 5-A and 5.3 for sunscreen 5-B. The vehicle had no effect on erythema or edema when compared with the untreated groups. No pretreatment (….), vehicle (.-.-.-), sunscreen 5-A (- - -), and sunscreen 5-B (–-). Data are given as mean ± SEM. Journal of Investigative Dermatology 2000 114, 620-627DOI: (10.1046/j.1523-1747.2000.00946.x) Copyright © 2000 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 4 The sunscreen with the higher UVA-PF affords better immunoprotection. SSR dose–response for inhibition of CHS are shown; no pretreatment (….), vehicle (-.-.-.-), sunscreen 5-A (- - -) and sunscreen 5-B (–-). Data are given as mean ± SEM. (a) The immunoprotection afforded by product 5-A was significantly (p < 0.01) higher that obtained with product 5-B. The IPF and the IPF50 were obtained with the estimated MISD or ISD50 and PF are shown in Table 2. (b) The dose–response curves for the inhibition of CHS in the different experimental groups (with and without sunscreens) are superimposed when IPF to be 3.9 for sunscreen 5-A and 2.9 for sunscreen 5-B. These factors named IPFG were estimated as described in the Materials and Methods. Journal of Investigative Dermatology 2000 114, 620-627DOI: (10.1046/j.1523-1747.2000.00946.x) Copyright © 2000 The Society for Investigative Dermatology, Inc Terms and Conditions